UGANDA NATIONAL TUBERCULOSIS AND LEPROSY CONTROL PROGRAMME
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
Une liste de contrôle pour le nettoyage et la décontamination des terminaux destinés aux établissements de soins pour les patients atteints d'Ebola doit inclure le nettoyage et la désinfection minutieux de toutes les surfaces, l'élimination et le traitement approprié des articles contaminés,... ainsi que la désinfection de l'ensemble de la zone, y compris les endroits difficiles d'accès, à l'aide de méthodes et de produits appropriés.
more
This guide to local production of WHO-recommended handrub formulations is separated into two discrete but interrelated sections:
Part A provides a practical guide for use at the pharmacy bench during the actual preparation of the formulation. Users may want to display the material on the wall of ...the production unit.
Part B summarizes some essential background technical information and is taken from WHO Guidelines on Hand Hygiene in Health Care (2009). Within Part B the user has access to important safety and cost information and supplementary material relating to dispensers and distribution.
more
last updated 29 March 2016
El propósito de este documento es proporcionar orientación sobre la limpieza y desinfección de las superficies ambientales en el contexto de COVID-19. Esta orientación está destinada a los profesionales de la salud, los profesionales de la salud pública y las autoridades sanitarias que están ...elaborando y aplicando políticas y procedimientos operativos estándar (POE) sobre la limpieza y desinfección de las superficies ambientales en el contexto de COVID-19.
more
This technical briefing paper details the construction and setup of medical isolation facilities in support of infectious disease outbreak responses.
IPC Training manual Day 2
Цель настоящего документа - дать указания по очистке и дезинфекции поверхностей окружающей среды в контексте КОВИД-19. Настоящее руководство предназначено для раб...тников здравоохранения, специалистов в области общественного здравоохранения и органов здравоохранения, которые разрабатывают и осуществляют политику и стандартные оперативные процедуры (СОП) по очистке и дезинфекции поверхностей окружающей среды в контексте КОВИД-19.
Переведено с помощью www.DeepL.com/Translator (бесплатная версия)
more
In light of the decline in new Ebola cases, strategies are now needed to scale down the activities and bed capacities in Ebola care facilities. These facilities include Ebola treatment units, community care centres, Ebola treatment centres and isolation centres. The Governments of Guinea, Liberia an...d Sierra Leone; WHO; CDC; ICAN and UNICEF have jointly developed this rapid guidance and checklist to assist national governments and partners as they begin this process. This rapid guidance pertains to protecting the safety and repurposing of infrastructures and resources previously used for the Ebola outbreak to care for Ebola patients.
more
The purpose of this document is to provide guidance on the cleaning and disinfection of environmental surfaces in the context of COVID-19. This guidance is intended for health care professionals, public health professionals and health authorities that are developing and implementing policies and sta...ndard operating procedures (SOP) on the cleaning and disinfection of environmental surfaces in the context of COVID-19.
more
Quality clinical care is at the heart of a robust, effective response to outbreaks. Frontline health workers need evidence-based tools and training to provide safe, effective and quality clinical care.
The Clinical Management channel includes videos on a range of diseases, such as Ebola, diphther...ia and influenza. The channel also hosts a full course series on COVID-19 which covers a holistic pathway of care of a patient, from screening and triage to rehabilitation and palliative care.
more
Presentation is current through November 21, 2014 and will be updated every Friday by 5pm. For the most up-to-date information, please visit www.cdc.gov/ebola.
*Presentation contains materials from CDC, MSF, and WHO
The National Strategic Plan for Malaria Elimination in India (2023-2027) focuses on achieving malaria elimination by 2030, in alignment with the Global Technical Strategy. The document outlines the strategies, targets, and goals for malaria elimination, aiming for zero indigenous malaria cases by 20...27. It emphasizes district-based planning, robust surveillance systems, and enhancing case management and vector control. The plan stresses the importance of universal access to treatment, prevention, and data-driven decision-making. Furthermore, it encourages innovation and research in malaria elimination efforts, fostering multisectoral coordination and community engagement.
more
La Stratégie Nationale de Plaidoyer et de Mobilisation des Ressources en faveur de la Lutte contre le Paludisme 2024–2028 en République Démocratique du Congo vise à renforcer l’engagement politique, mobiliser des financements domestiques et internationaux et impliquer tous les secteurs (publ...ic, privé, société civile) pour réduire la mortalité liée au paludisme de 70 % et l’incidence de 50 % d’ici 2028.
Le document propose des actions concrètes : plaidoyer auprès des décideurs pour des budgets accrus, exonération des intrants antipaludiques, introduction du vaccin R21/Matrix-M, création de partenariats public-privé, implication des leaders communautaires et campagnes de sensibilisation via les médias. Il s’aligne sur la stratégie mondiale de l’OMS et promeut une approche multisectorielle, coordonnée par le Programme National de Lutte contre le Paludisme avec l’appui de partenaires comme l’USAID et Breakthrough ACTION.
more